Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1310) 1310
science & technology (1125) 1125
life sciences & biomedicine (1110) 1110
indans - therapeutic use (886) 886
male (852) 852
female (746) 746
indans - adverse effects (701) 701
aged (682) 682
piperidines - therapeutic use (606) 606
alzheimer disease - drug therapy (496) 496
middle aged (481) 481
cholinesterase inhibitors - therapeutic use (453) 453
donepezil (441) 441
piperidines - adverse effects (430) 430
treatment outcome (407) 407
biological and medical sciences (399) 399
indans - administration & dosage (399) 399
medical sciences (385) 385
neurosciences & neurology (359) 359
pharmacology & pharmacy (339) 339
cholinesterase inhibitors - adverse effects (327) 327
alzheimer's disease (320) 320
clinical neurology (292) 292
aged, 80 and over (288) 288
double-blind method (282) 282
indans - pharmacology (280) 280
psychiatry (270) 270
adult (258) 258
pharmacology. drug treatments (243) 243
neurology (238) 238
animals (232) 232
drug therapy (225) 225
nootropic agents - therapeutic use (222) 222
piperidines - administration & dosage (185) 185
geriatrics & gerontology (183) 183
dose-response relationship, drug (179) 179
neurosciences (168) 168
nootropic agents - adverse effects (162) 162
rivastigmine (161) 161
neuropharmacology (152) 152
severity of illness index (149) 149
pulmonary disease, chronic obstructive - drug therapy (147) 147
dementia (145) 145
drug therapy, combination (143) 143
parkinson disease - drug therapy (142) 142
cholinesterase inhibitors - administration & dosage (138) 138
psychology. psychoanalysis. psychiatry (137) 137
degenerative and inherited degenerative diseases of the nervous system. leukodystrophies. prion diseases (135) 135
neuropsychological tests (133) 133
cholinesterase inhibitors (132) 132
indans - pharmacokinetics (132) 132
alzheimers disease (130) 130
galantamine - therapeutic use (123) 123
time factors (123) 123
abridged index medicus (122) 122
piperidines - pharmacology (119) 119
alzheimer disease - psychology (114) 114
randomized controlled trials as topic (113) 113
quinolones - administration & dosage (112) 112
cholinesterase inhibitors - pharmacology (110) 110
drug administration schedule (110) 110
general & internal medicine (110) 110
psychopharmacology (107) 107
care and treatment (106) 106
parkinson's disease (106) 106
clinical trials (105) 105
research (102) 102
cognition - drug effects (101) 101
indacaterol (101) 101
medicine, general & internal (99) 99
respiratory system (98) 98
cognition disorders - drug therapy (97) 97
analysis (96) 96
gerontology (96) 96
phenylcarbamates - therapeutic use (94) 94
quinolones - adverse effects (94) 94
quinolones - therapeutic use (94) 94
rats (94) 94
medicine & public health (93) 93
clinical trials as topic (92) 92
bronchodilator agents - administration & dosage (86) 86
dementia - drug therapy (86) 86
rasagiline (86) 86
psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (84) 84
drug interactions (83) 83
pulmonary disease, chronic obstructive - physiopathology (82) 82
dosage and administration (80) 80
memantine - therapeutic use (80) 80
lung diseases, obstructive (78) 78
cognition (77) 77
galantamine - adverse effects (75) 75
internal medicine (72) 72
pharmacology/toxicology (72) 72
bronchodilator agents - therapeutic use (70) 70
chronic obstructive pulmonary disease (70) 70
psychopathology. psychiatry (70) 70
bronchodilator agents - adverse effects (68) 68
piperidines - pharmacokinetics (68) 68
cross-over studies (66) 66
neuroprotective agents - therapeutic use (66) 66
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1408) 1408
German (17) 17
Japanese (16) 16
Spanish (14) 14
French (11) 11
Danish (4) 4
Chinese (3) 3
Hungarian (2) 2
Portuguese (2) 2
Dutch (1) 1
Finnish (1) 1
Italian (1) 1
Norwegian (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Sponging off nature for new drug leads
by Andersen, Raymond J
Biochemical pharmacology, ISSN 0006-2952, 09/2017, Volume 139, pp. 3 - 14
Porifera | Marine natural products | Drug discovery | Indans - adverse effects | Anti-Asthmatic Agents - therapeutic use | Humans | Drugs, Investigational - therapeutic use | Antineoplastic Agents - therapeutic use | Prodrugs - chemistry | Nonsteroidal Anti-Androgens - chemistry | Oligopeptides - therapeutic use | Nonsteroidal Anti-Androgens - therapeutic use | Sterols - adverse effects | Glycerol - analogs & derivatives | Porifera - chemistry | Benzhydryl Compounds - therapeutic use | Oligopeptides - chemistry | Anti-Asthmatic Agents - chemistry | Glycerol - therapeutic use | Indans - chemistry | Anti-Asthmatic Agents - pharmacology | Pyrrolidinones - adverse effects | Antimitotic Agents - adverse effects | Pyrrolidinones - therapeutic use | Antimitotic Agents - therapeutic use | Biological Products - isolation & purification | Biological Products - chemistry | Pyrrolidinones - isolation & purification | Cyclohexanols - therapeutic use | Oligopeptides - pharmacology | Anti-Asthmatic Agents - adverse effects | Cyclohexanols - adverse effects | Drugs, Investigational - adverse effects | Drugs, Investigational - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Oligopeptides - adverse effects | Indans - therapeutic use | Benzhydryl Compounds - chemistry | Drugs, Investigational - chemistry | Sterols - therapeutic use | Benzhydryl Compounds - adverse effects | Antineoplastic Agents - adverse effects | Cyclohexanols - chemistry | Nonsteroidal Anti-Androgens - adverse effects | Drug Design | Antineoplastic Agents - pharmacology | Glycerol - pharmacology | Aquatic Organisms - chemistry | Nonsteroidal Anti-Androgens - pharmacology | Sterols - pharmacology | Sterols - chemistry | Antineoplastic Agents - chemistry | Drug Discovery | Pyrrolidinones - chemistry | Prodrugs - adverse effects | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antimitotic Agents - pharmacology | Benzhydryl Compounds - pharmacology | Prodrugs - therapeutic use | Prodrugs - pharmacology | Antimitotic Agents - chemistry | Chemical oceanography | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Drug‐induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)
by Poluzzi, Elisabetta and Raschi, Emanuel and Moretti, Ugo and De Ponti, Fabrizio
Pharmacoepidemiology and drug safety, ISSN 1053-8569, 06/2009, Volume 18, Issue 6, pp. 512 - 518
torsades de pointes | FDA | spontaneous reports | disproportionality | adverse drug reaction | Disproportionality | Adverse drug reaction | Spontaneous reports | Torsades de pointes | Pharmacology & Pharmacy | Public, Environmental & Occupational Health | Life Sciences & Biomedicine | Science & Technology | Indans - adverse effects | Adverse Drug Reaction Reporting Systems | United States | Antipsychotic Agents - adverse effects | Humans | Databases, Factual - statistics & numerical data | Torsades de Pointes - chemically induced | Famotidine - adverse effects | Amiodarone - adverse effects | Piperidines - adverse effects | Anti-Bacterial Agents - adverse effects | Methadone - adverse effects | Antidepressive Agents - adverse effects | Cardiovascular Agents - adverse effects | Mitoxantrone - adverse effects | United States Food and Drug Administration | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis
by Tan, Chen-Chen
Journal of Alzheimer's disease, ISSN 1387-2877, 2014, Volume 41, Issue 2, pp. 615 - 631
rivastigmine | memantine | safety | donepezil | meta-analysis | systematic review | Alzheimer's disease | galantamine | efficacy | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Indans - adverse effects | Phenylcarbamates - therapeutic use | Humans | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Phenylcarbamates - adverse effects | Nootropic Agents - adverse effects | Indans - therapeutic use | Randomized Controlled Trials as Topic | Cholinesterase Inhibitors - administration & dosage | Galantamine - therapeutic use | Piperidines - therapeutic use | Rivastigmine | Piperidines - adverse effects | Galantamine - adverse effects | Memantine - therapeutic use | Memantine - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study
by Vogelmeier, Claus F, Prof and Bateman, Eric D, Prof and Pallante, John, BS and Alagappan, Vijay KT, MD and D'Andrea, Peter, MD and Chen, Hungta, PhD and Banerji, Donald, MD
The lancet respiratory medicine, ISSN 2213-2600, 2013, Volume 1, Issue 1, pp. 51 - 60
Pulmonary/Respiratory | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Sympathomimetics - administration & dosage | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Indans - therapeutic use | Quinolones - adverse effects | Quinolones - therapeutic use | Female | Indans - administration & dosage | Glucocorticoids - adverse effects | Sympathomimetics - adverse effects | Glycopyrrolate - adverse effects | Sympathomimetics - therapeutic use | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Administration, Inhalation | Albuterol - analogs & derivatives | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Albuterol - therapeutic use | Androstadienes - therapeutic use | Fluticasone-Salmeterol Drug Combination | Androstadienes - adverse effects | Albuterol - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs
by Cassels, Alan and Hughes, Merrilee A and Cole, Carol and Mintzes, Barbara and Lexchin, Joel and McCormack, James P
Canadian Medical Association journal, ISSN 0008-4409, 04/2003, Volume 168, Issue 9, pp. 1133 - 1137
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Indans - adverse effects | Raloxifene Hydrochloride - adverse effects | Humans | Heptanoic Acids - adverse effects | Newspapers as Topic | Bibliometrics | Drug-Related Side Effects and Adverse Reactions | Acetamides - adverse effects | Pyrroles - adverse effects | Patient Education as Topic | Pyrazoles | Consumer Product Safety | Drug Industry | Celecoxib | Disclosure | Drug Prescriptions | Anticholesteremic Agents - adverse effects | Atorvastatin Calcium | Canada | Oseltamivir | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Antiviral Agents - adverse effects | Piperidines - adverse effects | Estrogen Antagonists - adverse effects | Cholinesterase Inhibitors - adverse effects | Sulfonamides - adverse effects | Advertising as Topic | Prescription drugs | Media coverage | Index Medicus | Abridged Index Medicus | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial
by Wilkinson, David, Dr and Windfeld, Kristian, PhD and Colding-Jørgensen, Eskild, MD
Lancet neurology, ISSN 1474-4422, 2014, Volume 13, Issue 11, pp. 1092 - 1099
Neurology | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Indans - adverse effects | Receptors, Serotonin - physiology | Benzylamines - adverse effects | Follow-Up Studies | Humans | Male | Indans - therapeutic use | Alzheimer Disease - diagnosis | Serotonin Antagonists - adverse effects | Aged, 80 and over | Female | Alzheimer Disease - psychology | Cognition Disorders - psychology | Double-Blind Method | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Serotonin Antagonists - therapeutic use | Treatment Outcome | Cognition Disorders - drug therapy | Nootropic Agents - adverse effects | Cognition Disorders - diagnosis | Indoles - adverse effects | Piperidines - therapeutic use | Piperidines - adverse effects | Indoles - therapeutic use | Aged | Benzylamines - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey
by Vardigan, Joshua D and Vardigan, Joshua D and Cannon, Christopher E and Cannon, Christopher E and Puri, Vanita and Puri, Vanita and Dancho, Mandy and Dancho, Mandy and Koser, AmyJo and Koser, AmyJo and Wittmann, Marion and Wittmann, Marion and Kuduk, Scott D and Kuduk, Scott D and Renger, John J and Renger, John J and Uslaner, Jason M and Uslaner, Jason M
Psychopharmacology, ISSN 0033-3158, 6/2015, Volume 232, Issue 11, pp. 1859 - 1866
Neurosciences | Xanomeline | Biomedicine | Muscarinic | Donepezil | Side-effects | Cognition | Pharmacology/Toxicology | Acetylcholinesterase | Psychiatry | Alzheimer’s | Alzheimer's | Pharmacology & Pharmacy | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Muscarinic Agonists - pharmacology | Humans | Male | Macaca mulatta | Piperidines - pharmacology | Receptor, Muscarinic M1 - drug effects | Attention - drug effects | Female | Problem Solving - drug effects | Thiadiazoles - pharmacology | Piperidines - toxicity | Quinolizines - toxicity | Salivation - drug effects | Defecation - drug effects | Alzheimer Disease - drug therapy | Quinolizines - pharmacology | Cognition - drug effects | Neuropsychological Tests | Thiadiazoles - toxicity | Orientation - drug effects | Animals | Pyridines - toxicity | Indans - toxicity | Aged | Pyridines - pharmacology | Appetitive Behavior - drug effects | Indans - pharmacology | Research | Drug therapy | Alzheimer's disease | Side effects | Alzheimers disease | Monkeys & apes | Psychopharmacology | Animal cognition | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study
by Buhl, Roland and Gessner, Christian and Schuermann, Wolfgang and Foerster, Karin and Sieder, Christian and Hiltl, Simone and Korn, Stephanie
Thorax, ISSN 0040-6376, 04/2015, Volume 70, Issue 4, pp. 311 - 319
Life Sciences & Biomedicine | Respiratory System | Science & Technology | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Ethanolamines - administration & dosage | Indans - therapeutic use | Vital Capacity - drug effects | Quinolones - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Scopolamine Derivatives - administration & dosage | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Glycopyrrolate - adverse effects | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Ethanolamines - therapeutic use | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Analysis | Formoterol | Indacaterol | Dosage and administration | Diagnosis | Quality of life | Index Medicus | 1506 | Chronic Obstructive Pulmonary Disease | COPD Pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease
by Di Santo, Simona Gabriella and Prinelli, Federica and Adorni, Fulvio and Caltagirone, Carlo and Musicco, Massimo
Journal of Alzheimer's disease, ISSN 1387-2877, 2013, Volume 35, Issue 2, pp. 349 - 361
behavioral and psychological symptoms of dementia | Activities of daily living | memantine | meta-analysis | cholinesterase inhibitors | Alzheimer's disease | cognition disorders | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Indans - adverse effects | Neuroprotective Agents - therapeutic use | Humans | Middle Aged | Male | Indans - therapeutic use | Rivastigmine | Cognition - physiology | Female | Behavior | Neuroprotective Agents - adverse effects | Alzheimer Disease - psychology | Disability Evaluation | Data Interpretation, Statistical | Phenylcarbamates - therapeutic use | Alzheimer Disease - drug therapy | Phenylcarbamates - adverse effects | Treatment Outcome | Disease Progression | Randomized Controlled Trials as Topic | Neuropsychological Tests | Galantamine - therapeutic use | Piperidines - therapeutic use | Piperidines - adverse effects | Cholinesterase Inhibitors - adverse effects | Galantamine - adverse effects | Aged | Cholinesterase Inhibitors - therapeutic use | Memantine - therapeutic use | Memantine - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study
by Wedzicha, Jadwiga A, Prof and Decramer, Marc, Prof and Ficker, Joachim H, Prof and Niewoehner, Dennis E, Prof and Sandström, Thomas, Prof and Taylor, Angel Fowler, RPh and D'Andrea, Peter, MD and Arrasate, Christie, BS and Chen, Hungta, PhD and Banerji, Donald, MD
The lancet respiratory medicine, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 199 - 209
Pulmonary/Respiratory | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Dose-Response Relationship, Drug | Quinolones - adverse effects | Scopolamine Derivatives - administration & dosage | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Respiratory Function Tests - methods | Administration, Inhalation | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Disease Progression | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Respiratory System - drug effects | Respiratory System - physiopathology | Aged | Drug Monitoring | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Adverse Drug Reactions Reported With Cholinesterase Inhibitors : An Analysis of 16 Years of Individual Case Safety Reports From VigiBase
by Kroeger, Edeltraut and Mouls, Marie and Wilchesky, Machelle and Berkers, Mieke and Carmichael, Pierre-Hugues and van Marum, Rob and Souverein, Patrick and Egberts, Toine and Laroche, Marie-Laure
The Annals of pharmacotherapy, ISSN 1060-0280, 11/2015, Volume 49, Issue 11, pp. 1197 - 1206
RIVASTIGMINE | DEMENTIA | METAANALYSIS | ALZHEIMERS-DISEASE | RISK | PREVALENCE | pharmacovigilance | Journal Article | DONEPEZIL | adverse drug reactions | Research Support, Non-U.S. Gov't | NATIONWIDE | cholinesterase inhibitors | GALANTAMINE | VigiBase | FRENCH PHARMACOVIGILANCE DATABASE | Alzheimer's disease | Alzheimer’s disease | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Indans - adverse effects | Medication Errors | World Health Organization | Adverse Drug Reaction Reporting Systems | Rivastigmine - adverse effects | Europe | Humans | Alzheimer Disease - drug therapy | Drug-Related Side Effects and Adverse Reactions - etiology | Male | Pharmacovigilance | North America | Piperidines - adverse effects | Aged, 80 and over | Cholinesterase Inhibitors - adverse effects | Female | Galantamine - adverse effects | Aged | Index Medicus | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights